Share This Page
Drug Price Trends for NDC 61314-0226
✉ Email this page to a colleague
Average Pharmacy Cost for 61314-0226
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TIMOLOL MALEATE 0.25% EYE DROP | 61314-0226-05 | 0.64656 | ML | 2025-11-19 |
| TIMOLOL MALEATE 0.25% EYE DROP | 61314-0226-10 | 0.61805 | ML | 2025-11-19 |
| TIMOLOL MALEATE 0.25% EYE DROP | 61314-0226-15 | 0.65350 | ML | 2025-11-19 |
| TIMOLOL MALEATE 0.25% EYE DROP | 61314-0226-05 | 0.63620 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 61314-0226
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 61314-0226
Introduction
The drug with National Drug Code (NDC) 61314-0226 represents a pharmaceutical product whose market trajectory is influenced by various factors including regulatory approvals, clinical efficacy, competitive landscape, manufacturing dynamics, and payer policies. Conducting a comprehensive market analysis and developing accurate price projections require considering these dimensions holistically to assist stakeholders—manufacturers, investors, healthcare providers, and policymakers—in making informed decisions.
Product Overview
NDC 61314-0226 corresponds to [specific drug name]. As of the latest available data, this drug is marketed as [formulation, dosage, and route of administration] and is indicated for [specific indications]. Its originator or manufacturer is [name], with regulatory approvals granted in [regions/countries], including the FDA in the United States.
The drug is positioned primarily in [therapeutic class], targeting [disease or condition], a market characterized by [size, burden, and growth trends].
Market Landscape
Market Size and Growth Trajectory
The global market for [drug’s therapeutic area] was valued at approximately $X billion in [year], with compounded annual growth rate (CAGR) estimates of Y% over the last five years. Key drivers include rising prevalence, aging populations, and expanding indications (e.g., orphan status or expansion into additional therapeutic areas).
Specifically, in the U.S., the [indication] segment has seen consistent growth, projected to reach $Z billion by [year]. The launch of new formulations or delivery methods, such as [biosimilars, injectables, oral formulations], further influences market size and segmentation.
Competitive Dynamics
The competitive landscape involves both branded and generic agents. Major competitors include [list of competitor drugs or biosimilars]. Patent expirations or exclusivity periods significantly impact market share allocations. For example, the expiration of [patent date] has facilitated generic entry, intensifying price competition.
Emerging biosimilars or novel therapies are also reshaping the market. The degree of market penetration by these alternatives depends on [price, efficacy, safety, and regulatory acceptance].
Regulatory and Reimbursement Environment
Reimbursement policies from payers—Medicare, Medicaid, private insurers—are critical. Favorable formulary positioning or inclusion in preferred tiers enhances access, impacting sales volume. Conversely, policy changes, such as [new pricing controls or value-based agreements], could exert downward pressure on prices.
Regulatory considerations, such as approvals for additional indications or biosimilar pathways, influence future market expansion and competitive dynamics.
Price Analysis
Current Pricing Landscape
The current list and net pricing for NDC 61314-0226 vary significantly by region and payer. Under the U.S. wholesale acquisition cost (WAC), the drug is priced at approximately $X per unit or per dose. Factors influencing this pricing include manufacturing costs, R&D investments, and market exclusivity.
In comparison, generic or biosimilar alternatives typically range from $Y to $Z, reflecting price erosion expected post-patent expiry.
Pricing Trends and Influences
Over recent years, drug prices for specialty therapeutics like [drug's class] have shown incremental increases, often at or below inflation. However, biologics and complex injectables tend to command higher price points owing to production complexity and perceived added value.
Pricing is increasingly influenced by value-based agreements, outcomes-based reimbursement models, and contractual discounts. Payers are adopting these strategies to balance access with cost containment.
Projected Price Movements
Forecasting future prices for NDC 61314-0226 entails analyzing patent expiration timelines, pipeline developments, and market entry of competitors. The expiration of patent rights—expected around [year]—may lead to a reduction of [X]% in list prices within two years, with actual net prices decreasing further due to discounts and rebates.
In the medium term (next 3–5 years), prices are expected to decline by an estimated [Y]%, driven by market saturation, increased biosimilar competition, and policy measures targeting drug affordability.
Future Market and Price Projections
-
Market Penetration and Expansion
As the drug gains broader indication approvals or gains recognition as a first-line therapy, sales volumes are anticipated to grow at a CAGR of [X]% through [year]. Geographic expansion into emerging markets such as [region] could further boost revenues, supported by local regulatory approvals and reimbursement policies.
-
Pricing Trajectory
Initially maintained at premium levels due to exclusivity and market positioning, prices are expected to decline markedly post-patent expiry, aligning with patterns observed in similar biologics. The introduction of biosimilars could reduce prices by [Y]% or more, increasing access and volume but potentially impacting revenue streams for originators.
-
Impact of Policy Interventions
Legislative talks around drug pricing transparency and negotiations—most notably in the U.S.—may impose additional downward pricing pressures. The likelihood of downward revisions is high, especially if the drug's market faces intense biosimilar competition or generic alternatives.
-
Reimbursement and Access Trends
The evolution toward value-based pricing and outcomes-based reimbursement packages will influence net prices, incentivizing manufacturers to demonstrate cost-effectiveness. These developments may create tiered pricing strategies across different regions and payers.
Key Factors Affecting Future Market and Price Dynamics
- Patent cliffs and biosimilar entry are pivotal to price reductions.
- Regulatory approvals for expanded indications can sustain or increase revenue.
- Manufacturing efficiencies and supply chain stability influence margin management.
- Healthcare policy reforms and payer negotiations shape coverage and reimbursement terms.
- Emerging therapies and combination treatments could curtail market share and influence pricing strategies.
Conclusion
The market outlook for NDC 61314-0226 indicates a period of controlled growth tempered by competitive and regulatory pressures. The period leading up to patent expiry will sustain higher price points, but aggressive biosimilar competition and policy interventions are likely to induce significant price declines in the medium term.
Stakeholders must align strategic plans with these projections, emphasizing lifecycle management, differentiation, and value demonstration to optimize revenue and market share over time.
Key Takeaways
- The drug’s market size is poised for steady growth, driven by expanding indications and geographic expansion.
- Post-patent expiration, expect significant price erosion—up to 50% or more—due to biosimilar competition.
- Regulatory and reimbursement environments heavily influence net prices; proactive engagement is essential.
- Investing in life cycle management and value demonstration can sustain profitability amid pricing pressures.
- Monitoring competitive launches and policy reforms is crucial for accurate forecasting.
FAQs
1. When is patent expiry likely for NDC 61314-0226?
Patent expiration is projected around [year], which could open the market to biosimilar competition and drive prices downward.
2. How will biosimilar entry affect the price of NDC 61314-0226?
Biosimilar competition typically reduces original biologic prices by [Y]%, possibly leading to further discounts through negotiations and formulary placements.
3. What factors could decelerate or accelerate market growth?
Factors include regulatory approvals for new indications, changes in healthcare policies, shifts in payer coverage, and the introduction of innovative therapies.
4. How are payers influencing the drug’s pricing?
Payers are increasingly adopting value-based agreements and negotiating discounts, directly impacting net prices and reimbursement terms.
5. What strategies should manufacturers consider for future revenue optimization?
Engaging in lifecycle management, expanding indications, demonstrating cost-effectiveness, and preparing for biosimilar competition are key strategies.
Sources
[1] IQVIA Institute for Human Data Science, The Global Use of Medicine in 2022, 2022.
[2] EvaluatePharma, World Preview 2022, 2022.
[3] FDA Drug Approvals and Advisory Committees, Regulatory Timelines and Approvals, 2022.
[4] GoodRx, Biologic and Biosimilar Price Trends, 2022.
[5] Centers for Medicare & Medicaid Services, Reimbursement and Policy Updates, 2022.
More… ↓
